Application of xanthone compounds in mangosteen to preparation of products for preventing and treating plant diseases

Abstract

The invention provides application of xanthone compounds in mangosteen to preparation of products for preventing and treating plant diseases, and belongs to the field of natural medicinal chemistry. The xanthone compound in the mangosteen is used for preparing a product for preventing and / or treating plant diseases caused by pathogenic bacteria. The xanthone compound in the mangosteen is at least one of the following components: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-isomangostin, and the xanthone compound in the mangosteen is selected from the group consisting of 1-isomangostin, 1-isomangostin, 1-isomangostin, 1-isomangostin, 1-isomangostin, 1-isomangostin, 1-isomangostin and 1-isomangostin. The xanthone compound in the mangosteen has the advantages of being green, efficient, low in toxicity, wide in antibacterial spectrum, low in residue, not prone to generating resistance and the like; the application value is realized in the aspect of preventing and controlling agricultural common pathogenic bacteria.

Description

Technical Field

[0001] The invention relates to the field of natural drug chemistry, and in particular to use of xanthone compounds in mangosteen in preparing products for preventing and treating plant diseases. Background Art

[0002] Plant pathogens are one of the most harmful plant pathogens in modern agricultural planting, which can cause serious plant diseases and crop yield reduction. Once pathogenic microorganisms infect plants, they will not only seriously affect the natural growth of plants, but also directly affect the yield and quality of crops. In order to ensure the normal and orderly progress of modern agricultural production, in addition to implementing necessary protective measures during the production process, a certain amount of agricultural protection agents are also needed to prevent and control plant pathogens.

[0003] At present, in modern agricultural planting, chemical agents (such as fungicides, etc.) for preventing and controlling plant pathogens still dominate the prevention and control of crop diseases. However, the long-term irrational use of traditional chemical fungicides will lead to prominent problems such as pesticide residues, drug resistance, and rampant pest resurgence (3R), and there is still a lack of effective solutions. This has greatly affected agricultural production and caused a reduction in farmers' income. In order to achieve sustainable agricultural development, finding plant protection products with low toxicity, low residue and good environmental compatibility is one of the main goals of the development of agricultural agents today.

[0004] Plant resources are active natural products, which produce more than 400,000 secondary metabolites, most of which have good antibacterial activity. Natural products have always been an important source in drug research and development. In the past two decades, more than one-third of FDA-approved drugs are natural products and their derivatives. Compared with chemically synthesized compounds, natural products have some unique properties, such as higher structural complexity, more novel skeletons, and better drug-like properties. Therefore, natural products are a treasure trove that deserves special attention and have great potential for the research and development of agricultural agents.

[0005] Mangosteen is the fruit of the evergreen tree mangosteen, belonging to the family Garcinia and the genus Garcinia. In Thailand, mangosteen has been used as a traditional medicine to treat abdominal pain, diarrhea, dysentery and other diseases. The main metabolites of mangosteen husk are oxidized anthraquinones, among which α-mangostin is its classic representative compound. It is abundant in mangosteen and has significant anti-inflammatory, antioxidant and anti-tumor effects, with high activity, low toxicity and few side effects. At the same time, mangosteen also contains a large number of other abundant metabolites (such as xanthone compounds). It is of great technical significance to further develop and expand the application field of mangosteen and study and develop the potential application value of active ingredients in mangosteen in preventing and controlling plant pathogens. Summary of the invention

[0006] In order to solve the technical problems existing in the prior art, the present invention provides a use of xanthone compounds in mangosteen in preparing products for preventing and treating plant diseases; in particular, the use of xanthone compounds in mangosteen in preparing products for preventing and / or treating plant diseases caused by pathogenic bacteria.

[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows: Use of xanthone compounds in mangosteen in preparing products for preventing and treating plant diseases, and use of xanthone compounds in mangosteen in preparing products for preventing and / or treating plant diseases caused by pathogenic bacteria; The xanthones in the mangosteen are at least one of the following: α-mangostin, β-mangostin, γ-mangostin, garcinone C, garcinone D, Gartanin, brasilixanthone B, garcinone E, 1-Isomangostin; The chemical structural formula of the xanthone compounds in each of the mangosteens is: ; The pathogens include: Xanthomonas oryzae, the pathogen of rice bacterial blight, Xanthomonas axonopodis pv. Citri, the pathogen of citrus canker, Pseudomonas sollamacearum, the pathogen of tomato bacterial wilt, Ralstonia solanacearum, and Erwinia aroideae, the pathogen of soft rot.

[0008] Furthermore, the product includes: a pharmaceutical composition and an antibacterial agent.

[0009] A pharmaceutical composition for preventing and / or treating plant diseases caused by the aforementioned pathogenic bacteria, prepared by using at least one xanthone compound in mangosteen as an effective ingredient or main effective ingredient; The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

[0010] An antibacterial agent for the aforementioned pathogenic bacteria is prepared by using at least one xanthone compound in mangosteen as an effective component or a main effective component.

[0011] The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

[0012] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention uses xanthone compounds in mangosteen to conduct antibacterial activity tests on rice bacterial blight pathogen Xanthomonasoryzae, citrus canker pathogen Xanthomonas axonopodis pv. Citri, tomato bacterial wilt pathogen Pseudomonas sollamacearum, Ralstonia solanacearum, and soft rot pathogen Erwiniaaroideae. The xanthone compounds in mangosteen show a certain inhibitory effect on each pathogen, and can be effectively used in the preparation of products for preventing and / or treating plant diseases caused by the aforementioned pathogens, further expanding the application field of xanthone compounds in mangosteen, and having great application value and application prospects in preventing and controlling common agricultural pathogens.

[0013] (2) The present invention uses xanthones in mangosteen as a natural source antibacterial agent, which is easy to prepare and has the advantages of being green, efficient, low toxicity, a broad antibacterial spectrum, low residue and not easy to develop resistance. In addition, mangosteen resources are abundant and easy to obtain. It is green, efficient, and not easy to develop drug resistance. It has application value in preventing and controlling common agricultural pathogens and is worthy of further research and development.

[0014] (3) The xanthones in mangosteen of the present invention show certain antibacterial activity against Xanthomonasoryzae, the pathogen of rice bacterial blight, Xanthomonas axonopodis pv. Citri, the pathogen of citrus canker, Pseudomonas sollamacearum, the pathogen of tomato bacterial wilt, Ralstonia solanacearum, and Erwiniaaroideae. Among them, each xanthone compound showed excellent antibacterial activity against citrus canker pathogens; S3 / γ-mangostin had the most significant antibacterial activity against citrus canker pathogens, with a MIC value of 6.25μg / mL; S5 / garcinone D had a MIC value of 12.5μg / mL against citrus canker pathogens; S8 / garcinoneE had a MIC value of 25μg / mL against citrus canker pathogens, with excellent antibacterial activity; they can be used as active ingredients or main active ingredients to prepare products (such as pharmaceutical compositions, antibacterial agents, etc.) for the prevention and / or treatment of related diseases caused by the aforementioned pathogens. DETAILED DESCRIPTION

[0015] In order to have a clearer understanding of the technical features, purposes and effects of the present invention, the specific implementation methods of the present invention are now described.

[0016] The embodiment of the present invention provides a use of a xanthone compound in mangosteen in preparing a product for preventing and treating plant diseases, and the use of the xanthone compound in mangosteen in preparing a product for preventing and / or treating plant diseases caused by pathogenic bacteria; The xanthones in the mangosteen are at least one of the following: S1 / α-mangostin, S2 / β-mangostin, S3 / γ-mangostin, S4 / garcinone C, S5 / garcinone D, S6 / Gartanin, S7 / brasilixanthoneB, S8 / garcinone E, S9 / 1-Isomangostin; The chemical structural formula of the xanthone compounds in each of the mangosteens is: ; The pathogens include: Xanthomonas oryzae, the pathogen of rice bacterial blight, Xanthomonas axonopodis pv. Citri, the pathogen of citrus canker, Pseudomonas sollamacearum, the pathogen of tomato bacterial wilt, Ralstonia solanacearum, and Erwinia aroideae, the pathogen of soft rot.

[0017] Furthermore, the product includes: a pharmaceutical composition and an antibacterial agent.

[0018] The embodiment of the present invention also provides a pharmaceutical composition for preventing and / or treating plant diseases caused by the aforementioned pathogenic bacteria, which is prepared by using at least one xanthone compound in mangosteen as an effective ingredient or main effective ingredient; The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

[0019] The embodiment of the present invention also provides an antibacterial agent for the aforementioned pathogenic bacteria, which is prepared by using at least one xanthone compound in mangosteen as an effective ingredient or a main effective ingredient; The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

[0020] Example 1 Determination of the antibacterial activity of xanthones in mangosteen against agricultural bacterial pathogens: 1) Test agents: commercially available α-mangostin, S1 / α-mangostin, S2 / β-mangostin, S3 / γ-mangostin, S4 / garcinone C, S5 / garcinone D, S6 / Gartanin, S7 / brasilixanthone B, S8 / garcinone E, S9 / 1-Isomangostin.

[0021] Among the reagents used in this embodiment, except for the commercially available α-mangostin, which was purchased from commercial sources, the other reagents were extracted from mangosteen peel by conventional separation and extraction methods. The specific references for the extraction methods of S1 / α-mangostin, S2 / β-mangostin, S3 / γ-mangostin, S4 / garcinone C, S5 / garcinone D, S6 / Gartanin, S7 / brasilixanthone B, S8 / garcinone E, and S9 / 1-Isomangostin in the embodiments of the present invention are: Ma Tianfang, Study on Chemical Composition and Biological Activity of Mangosteen Peel, Zhengzhou University, 2020; Liu Yan, Study on Chemical Composition and Biological Activity of Mangosteen Peel, Jilin University, 2006; Xu Tao, Study on Chemical Composition and Pharmacological Action of Mangosteen Shell, Donghua University, 2016.

[0022] 2) Test strains: The pathogen of rice bacterial blight is Xanthomonas oryzae ACCC11602, the pathogen of citrus canker is Xanthomonas axonopodis pv.Citri, the pathogen of tomato bacterial wilt is Pseudomonas sollamacearum, Ralstonia solanacearum and the soft rot pathogen is Erwinia aroideae.

[0023] Among them, the pathogen of rice bacterial blight Xanthomonas oryzae ACCC11602 was purchased from the China Agricultural Microbiology Culture Collection Center (ACCC); the pathogen of citrus canker Xanthomonas axonopodis pv.Citri, the pathogen of tomato bacterial wilt Pseudomonas sollamacearum, Ralstonia solanacearum, and the soft rot pathogen Erwinia aroideae were all provided by Guangxi Tianyuan Biochemical Co., Ltd.

[0024] 3) Test method: The strain used in the test experiment of this embodiment is a strain frozen in 30% glycerol at a temperature of -80°C in the laboratory.

[0025] Each frozen strain was taken out and streaked on the NB solid medium of plant bacteria (beef extract: 3g, peptone: 5g, yeast powder: 1g, sucrose: 10g, agar: 15g, distilled water: 1L; pH 7.0; sterilized at 121℃ for 20min), and cultured at 28℃ until a single colony grew; the single colony on the solid medium was picked and placed on the NB solid medium of plant bacteria (beef extract: 3g, peptone: 5g, yeast powder: 1g, sucrose: 10g, agar: 15g, distilled water: 1L; pH 7.0; sterilized at 121℃ for 20min), and cultured at 28℃, 180rpm constant temperature shaker until the logarithmic growth phase. Each strain in the logarithmic growth phase was diluted to 10 with the corresponding liquid culture medium. 6 CFU / mL, obtain bacterial culture and set aside.

[0026] Dissolve each test drug (commercially available α-mangostin, α-mangostin, β-mangostin, γ-mangostin, garcinone C, garcinone D, Gartanin, brasilixanthone B, garcinoneE, 1-Isomangostin) in DMSO, add to the liquid culture medium, mix well, and prepare a drug-containing liquid culture medium with a concentration of 200 μg / mL. Take 50 μL of the drug-containing culture medium and the same volume of 10 6 CFU / mL of bacterial culture was added to the wells of a 96-well plate, and the final concentration of each test agent was controlled to be 100μg / mL; and 100μL of bacterial solution of the same concentration containing an equal amount of DMSO was used as the control group. The 96-well plate was cultured in a constant temperature incubator at 28℃ (37℃) for 24-48h until the bacterial solution of the control group grew, and the OD value (OD 600 ). In addition, the OD values ​​of 100 μL of liquid culture medium and the drug with a concentration of 100 μg / mL were measured to correct the OD values ​​caused by the culture medium and the drug itself. The calculation formula for the corrected OD value and inhibition rate is as follows: Corrected OD value = OD value of bacterial culture medium - OD value of sterile culture medium; Inhibition rate = [(corrected OD value of bacterial solution in control culture medium - corrected OD value of drug-containing culture medium) / corrected OD value of bacterial solution in control culture medium] × 100%.

[0027] All the above experiments were repeated three times, and the inhibition rate of each test agent on each test strain is shown in the following table:

[0028] As can be seen from the table above, the xanthone compounds (S1-S9) involved in this example all showed certain antibacterial activity against the tested bacteria. Among them, they showed excellent antibacterial activity against the pathogen of citrus canker; except for S4 / garcinone C and S7 / brasilixanthone B, the inhibition rates against the pathogen of citrus canker were all over 86%.

[0029] Example 2 On the basis of Example 1, the drug-containing liquid culture medium of each test agent was diluted in a 96-well plate by a two-fold dilution method to obtain 50 μL of drug-containing culture medium of a series of concentrations, and then the inhibition rate corresponding to the series of concentrations was determined according to the same test method in Example 1. The lowest concentration with an inhibition rate greater than 90% was defined as the minimum inhibitory concentration MIC, and the MIC value of each test agent for each test strain was determined. The specific determination results are shown in the following table:

[0030] It can be seen from the above content that the xanthone compounds (S1-S9) involved in this embodiment all showed certain antibacterial activity against the tested bacteria; among them, they showed excellent antibacterial activity against the pathogen of citrus canker. By comparison, the activity of S1 / α-mangostin isolated from mangosteen is equivalent to that of α-mangostin purchased from commercial sources, and its MIC value is 12.5-25μg / mL; among them, the antibacterial activity of S3 / γ-mangostin against citrus canker pathogen is the most significant, and its MIC value is 6.25μg / mL; the MIC value of S5 / garcinone D against citrus canker pathogen is 12.5μg / mL; the MIC value of S8 / garcinone E against citrus canker pathogen is 25μg / mL, and the antibacterial activity is excellent.

[0031] In summary, the xanthone compounds in mangosteen of the present invention show certain antibacterial activity against pathogens of plant diseases (Xanthomonas oryzae, the pathogen of rice bacterial blight, Xanthomonas axonopodis pv. Citri, the pathogen of citrus canker, Pseudomonas sollamacearum, the pathogen of tomato bacterial wilt, Ralstonia solanacearum and Erwinia aroideae), and can be used as effective ingredients or main effective ingredients to prepare products (such as pharmaceutical compositions, antibacterial agents, etc.) for preventing and / or treating related diseases caused by the aforementioned pathogens.

[0032] Unless otherwise specified, all percentages used in the present invention are by mass.

[0033] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A use of xanthone compounds in mangosteen in preparing products for preventing and controlling plant diseases, characterized in that: Use of the xanthone compounds in mangosteen in preparing products for preventing and / or treating plant diseases caused by pathogenic bacteria; The xanthones in the mangosteen are at least one of the following: α-mangostin, β-mangostin, γ-mangostin, garcinone C, garcinone D, Gartanin, brasilixanthone B, garcinone E, 1-Isomangostin; The pathogens include: Xanthomonas oryzae, the pathogen of rice bacterial blight, Xanthomonas axonopodis pv. Citri, the pathogen of citrus canker, Pseudomonas sollamacearum, the pathogen of tomato bacterial wilt, Ralstonia solanacearum, and Erwinia aroideae, the pathogen of soft rot.

2. The use of the xanthone compounds in mangosteen according to claim 1 in preparing products for preventing and controlling plant diseases, characterized in that: The products include: pharmaceutical compositions and antimicrobial agents.

3. A pharmaceutical composition for preventing and / or treating plant diseases caused by the pathogenic bacteria according to claim 1, characterized in that: It is prepared by using at least one xanthone compound in mangosteen as an effective ingredient or main effective ingredient; The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

4. An antibacterial agent for the pathogenic bacteria according to claim 1, characterized in that: It is prepared by using at least one xanthone compound in mangosteen as an effective ingredient or main effective ingredient; The xanthones in mangosteen are: alpha-mangostin, beta-mangostin, gamma-mangostin, garcinone C, garcinone D, gartanin, brasilixanthone B, garcinone E and 1-Isomangostin.

Images